Compare
Corvus Pharmaceuticals, Inc. vs Aldeyra Therapeutics, Inc. vs Werewolf Therapeutics, Inc. vs Incannex Healthcare Inc.
| Latest fiscal year | Corvus Pharmaceuticals, Inc. CRVS | Aldeyra Therapeutics, Inc. ALDX | Werewolf Therapeutics, Inc. HOWL | Incannex Healthcare Inc. IXHL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | n/a | n/a | $0 |
| Revenue growth (YoY) | n/a | n/a | n/a | -100.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$15.28M | -$33.85M | -$60.82M | -$19.30M |
| EPS (Diluted) | -$0.53 | -$0.56 | -$1.33 | -$1.66 |
| Operating cash flow | -$32.80M | -$33.35M | -$60.29M | -$12.87M |
| Free cash flow | -$32.97M | n/a | -$60.29M | -$12.88M |
| Cash & equivalents | $4.58M | $70.04M | $57.05M | $67.71M |
| Total assets | $71.12M | $72.06M | $69.40M | $72.98M |
| Total liabilities | $9.91M | $27.81M | $44.59M | $5.61M |
| Shareholders' equity | $61.20M | $44.25M | $24.80M | $67.37M |
| Return on year-end equity | -25.0% | -76.5% | -245.2% | -28.6% |
| Shares outstanding | 74.70M | 60.16M | 48.60M | 12.54M |
Revenue, most recent five fiscal years
| Fiscal year | Corvus Pharmaceuticals, Inc. | Aldeyra Therapeutics, Inc. | Werewolf Therapeutics, Inc. | Incannex Healthcare Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $0 Ended 2026-06-30 |
| 1 year earlier | n/a | n/a | n/a | $86.0K Ended 2025-06-30 |
| 2 years earlier | n/a | n/a | n/a | $12.0K Ended 2024-06-30 |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |